lamivudine has been researched along with ritonavir in 356 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 67 (18.82) | 18.2507 |
| 2000's | 118 (33.15) | 29.6817 |
| 2010's | 146 (41.01) | 24.3611 |
| 2020's | 25 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| D'Aquila, RT; De Pasquale, MP; Olson, DP; Scadden, DT | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Faulds, D; Lea, AP | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Cavert, W; Danner, SA; Gebhard, K; Goudsmit, J; Haase, AT; Henry, K; McDade, H; Mills, R; Notermans, DW; Schuwirth, CM; Staskus, K; Wietgrefe, SW; Zhang, ZQ; Zupancic, M | 1 |
| Heylen, R; Miller, R | 1 |
| Mueller, BU | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Feingold, A; Meislich, D; Rudy, B; Rutstein, RM; Word, B | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Feregrino-Goyos, M; Ortega-Larrocea, G | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Goldstein, H; Katopodis, NF; Kim, A; Kollmann, TR; Pettoello-Mantovani, M; Raker, C; Wiltshire, H; Yurasov, S | 1 |
| Cavert, W; Danner, SA; de Jong, JJ; de Wolf, F; Foudraine, NA; Goodwin, C; Goudsmit, J; Jurriaans, S; Kauffmann, RH; Leonard, JM; McDade, H; Meenhorst, PL; Notermans, DW; Schuwirth, CM | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Collins-Jones, TL; Davis, KF; Farley, JJ; Houck, DL; Rothman, MI; Tepper, VJ; Wachtel, RC | 1 |
| Bai, J; Daar, ES; Giorgi, JV; Hausner, MA; Majchrowicz, M; Tamaddon, M | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Dalod, M; Deschemin, JC; Dumon, B; Gomard, E; Harzic, M; Hoen, B; Levy, JP; Pellegrin, I; Sereni, D; Venet, A | 1 |
| Chiozzi, MH; Connick, E; Fox, L; Kessler, H; Kotzin, BL; Kuritzkes, DR; Landay, A; Lederman, MM; Leonard, JM; Martinez, A; Roe, JD; Rousseau, F; Spritzler, J; St Clair, M; Wade, M | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Mittler, J; Notermans, DW; Perelson, AS | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Beveridge, A; Carr, A; Cooper, DA; Cunningham, P; Duncombe, C; French, M; Kaufmann, GR; Sayer, D | 1 |
| Heald, AE; Pieper, CF; Schiffman, SS | 1 |
| Saag, MS; Schooley, RT | 1 |
| Battegay, M; Bisset, LR; Cone, RW; Grob, PJ; Huber, W; Opravil, M; Vernazza, PL; Weber, R | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Gilquin, J; Jubault, V; Kazatchkine, MD; Sert, C; Viard, JP | 1 |
| Flexman, J; French, MA; John, M | 1 |
| Dickinson, BP; Flanigan, T; Mega, A; Mileno, MD; Mylonakis, E; Rich, JD; Schiffman, FJ | 1 |
| Binley, JM; Cao, Y; Chaudhry, MR; Frankel, S; Heath-Chiozzi, M; Ho, DD; Hurley, A; J, X; Jin, X; Leonard, JM; Markowitz, M; Moore, JP; Nixon, DF; Racz, P; Talal, A; Tenner-Racz, K; Vesanen, M; Yaman, M | 1 |
| Phillips, L | 1 |
| Delfraissy, JF; Goujard, C; Guillet, JG; Lantz, O; Lefebvre, P; Martinon, F; Michelet, C; Peguillet, I; Taoufik, Y | 1 |
| Brunet, C; Chambost, H; Giraud, P; Michel, G; Perrimond, H; Tamalet, C; Thuret, I | 1 |
| Justesen, US; Mygind, LH; Pedersen, C; Pedersen, SS | 1 |
| Cassano, P; Clumeck, N; De Wit, S; Gerard, M; Hermans, P; Kabeya, K; O'Doherty, E | 1 |
| Arvieux, C; Bazin, C; Bellissant, E; Cartier, F; Chauvin, JP; Delfraissy, JF; Dohin, E; Michelet, C; Raffi, F; Renard, I; Ruffault, A; Sébille, V | 1 |
| Connick, E; Fox, L; Kessler, H; Kuritzkes, DR; Landay, A; Lederman, MM; Patki, AH; Purvis, SF; Spritzler, J; St Clair, M; Valdez, H | 1 |
| Cruceta, A; Gallart, T; García, F; Gatell, JM; Miró, JM; O'Brien, WA; Pantaleo, G; Plana, M; Pumarola, T; Vidal, C | 1 |
| Berkhout, B; Boucher, CA; Keulen, W; Schuurman, R; van Wijk, A | 1 |
| Battegay, M; Cone, RW; Hirschel, B; Ledergerber, B; Opravil, M; Vernazza, P; Zinkernagel, C | 1 |
| Danner, SA; Foudraine, NA; Goudsmit, J; Hamann, D; Kauffmann, RH; Meenhorst, PL; Miedema, F; Notermans, DW; Pakker, NG; Roos, MT; Schellekens, PT | 1 |
| Beauvais, L; Bicart-See, A; Bourezane, Y; Dubeaux, B; Dumon, B; Fleury, H; Harzic, M; Hoen, B; Lascoux, C; Raffi, F; Ragnaud, JM; Séréni, D; Venet, A | 1 |
| Black, FT; Blaxhult, A; Gerstoft, J; Jensen-Fangel, S; Kirk, O; Larsen, L; Lundgren, JD; Obel, N; Pedersen, C | 1 |
| Kikuchi, Y; Oka, S; Tachikawa, N; Yasuoka, A; Yoshizawa, S | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Connick, E; Kessler, H; Kuritzkes, D; Landay, AL; Lederman, MM; Olinger, G; Spear, GT; Spritzler, J; St Clair, M; Sullivan, BL; Wu, H | 1 |
| Connick, E; Francis, I; Gross, B; Kessler, HA; Kuritzkes, D; Landay, A; Lederman, MM; McCune, JM; Smith, KY; Spritzler, J; Valdez, H | 1 |
| Chiozzi, MH; Connick, E; D'Arc Roe, J; Fox, L; Kessler, H; Kotzin, BL; Kuritzkes, DR; Landay, A; Lederman, MM; Leonard, JM; Martinez, A; Rousseau, F; Sevin, AD; Spritzler, J; St Clair, M | 1 |
| Borkowsky, W; Fiscus, S; Jimenez, E; Lee, S; McIntosh, K; Mofenson, L; Nachman, SA; Pelton, S; Pitt, J; Rathore, M; Smith, ME; Stanley, K; Wells, B; Wiznia, A; Yogev, R | 1 |
| Bakhtiari, M; Connick, E; Kessler, H; Kuritzkes, DR; Landay, A; Lederman, MM; Sevin, A; Spritzler, J; St Clair, M; Wu, H; Young, B | 1 |
| Bassetti, S; Bisset, LR; Cone, RW; Fischer, M; Huber, W; Knuchel, MC; Lorenzi, P; Lüthy, R; Opravil, M; Ott, P; Roos, M; Vernazza, PL; Weber, R | 1 |
| Connick, E; Evans, TG; Fox, L; Heath-Chiozzi, M; Kessler, H; Kuritzkes, DR; Landay, A; Lederman, HM; Lederman, MB; Lederman, MM; Roe, J; Smith, KY; Spritzler, J; Valdez, H | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Bizzoni, L; Cassone, A; Girmenia, C; Martino, P; Mazzucconi, MG | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Danner, SA; Gisolf, EH; Hoetelmans, RW; van Heeswijk, RP | 1 |
| Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W | 1 |
| Burger, DM; Hoetelmans, RM; Jurriaans, S; Lange, JM; Portegies, P; Prins, JM; Sommadossi, JP; Turner-Foisy, ML; van Praag, RM; Weverling, GJ; Zhou, XJ | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Bryson, YJ; Deville, J; Equils, O; Garratty, E; Krogstad, P; Nielsen, K; Plaeger, S; Sim, MS; Tapia, M; Wei, LS | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Belohradsky, BH; Rolinski, B; Stojanov, S; Wintergerst, U | 1 |
| Neto, JL; Siciliano, RF | 1 |
| Kuritzkes, DR; Landay, AL; Lederman, MM; Mosier, DE; Picchio, GR; Sabbe, R; Valdez, H | 1 |
| Gallart, T; Garcia, F; Gatell, JM; Maleno, MJ; Miró, JM; Plana, M; Tortajada, C | 1 |
| Arnaiz, JA; Blanco, JL; Carné, X; Codina, C; Cruceta, A; García-Viejo, MA; Gatell, JM; Giner, V; Mallolas, J; Martínez, E; Pumarola, T; Sarasa, M; Soriano, A; Soy, D; Tuset, M | 1 |
| Benson, C; Bertz, R; Brun, S; Eron, JJ; Gulick, R; Hammer, S; Hicks, C; Hsu, A; Japour, A; Kessler, HA; King, M; Murphy, RL; Sun, E; Thompson, M; White, AC | 1 |
| Angelosante, W; Carneiro, M; Maneiro, P; Pérez, C; Sanchéz, A; Valleé, M | 1 |
| Chang, HE | 1 |
| Smart, T | 2 |
| Alcorn, K | 1 |
| Doepel, L; Folkers, G | 1 |
| Coppedge, B | 1 |
| Golk, M | 1 |
| Cunningham, S; Eshleman, SH; Jackson, JB; Johnson, G; Krogstad, P; Lee, S; Nachman, S; Palumbo, P; Wang, YG; Wantman, M; Wei, LJ; Wiznia, A | 1 |
| Funk, MB; Klingebiel, T; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Holodniy, M; Mole, L; Schmidgall, D | 1 |
| Battegay, M; Bisset, LR; Cone, RW; Dubs, RW; Fischer, M; Grob, PJ; Opravil, M; Vernazza, PL; Weber, R | 1 |
| Bakker, M; Cremers, J; Danner, SA; de Jong, JJ; de Ronde, A; Goudsmit, J; Hellings, JA; Nijholt, L; Notermans, DW; Roos, MT | 1 |
| Aaron, L; Carnot, F; Pialoux, G | 1 |
| Chadapaud, S; Chouraqui, M; Delbeke, E; Hittinger, G; Lafeuillade, A; Poggi, C | 1 |
| Chadapaud, S; Halfon, P; Hittinger, G; Khiri, H; Lafeuillade, A; Poggi, C | 1 |
| Craig, K | 1 |
| de Oliveira Pinto, LM; Gougeon, ML; Lecoeur, H; Ledru, E; Patey, O; Rapp, C | 1 |
| Aguayo, R; Dieudonne, A; Jackson, JB; Johnson, G; Khoury, M; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Stanley, K; Wiznia, A | 1 |
| Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A | 1 |
| Chaix, ML; Delfraissy, JF; Deveau, C; Dubeaux, B; Garrigue, I; Goujard, C; Harzic, M; Hoen, B; Meyer, L; Ngo, N; Pellegrin, I; Rouzioux, C; Sereni, D | 1 |
| Post, JJ | 1 |
| Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S | 1 |
| Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW | 1 |
| Bartlett, JG; Pham, P | 1 |
| Jiménez, FJ; Labarga, P; Pinilla, J; Repiso, M | 1 |
| Anderson, ML; Kawanishi, H; Shah, N; Vasseur, BG | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Brault, C; Chennebault, JM; Loison, J; Payan, C; Peigne, M | 1 |
| Singh, G | 1 |
| Bailey, VL; Bowles, FB; Finn, TS; Haas, DW; Harris, VL; Johnson, B; Nicotera, J; Raffanti, S; Saah, AJ; Schranz, J; Stone, J | 1 |
| Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
| Katano, H; Kimura, S; Niino, H; Oka, S; Teruya, K; Yamamoto, Y; Yasuoka, A | 1 |
| Benson, C; Bosch, RJ; Connick, E; Haas, DW; Kessler, H; Kim, RB; Kuritzkes, D; Landay, A; Lederman, MM; Li, H; Wilkinson, GR; Wu, H | 1 |
| Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E | 1 |
| Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad | 1 |
| Benson, C; Brun, SC; Eron, JJ; Gulick, RM; Hicks, C; Kessler, HA; King, KR; King, MS; Murphy, RL; White, AC | 1 |
| Fletcher, CV; McIntosh, K; Nachman, SA; Pelton, S; Stanley, K; Wiznia, A; Yogev, R | 1 |
| Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL | 1 |
| Béguinot, I; Burty, C; Christian, B; Grandidier, M; Jeanmaire, H; May, T; Penalba, C; Rabaud, C | 1 |
| Cuadrado, JM; Jover, F; Martínez-Baltanás, A; Roig, P | 1 |
| Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Murphy, RL | 1 |
| Abrams, EJ; Borkowsky, W; Britto, P; Chadwick, EG; Flynn, PM; Hughes, M; Luzuriaga, K; Palumbo, P; Powell, C; Rodman, JH; Yogev, R | 1 |
| Azuaje, C; Domingo, P; Falco, V; Gatell, JM; Lopez, RM; Lopez-Colomes, JL; Mallolas, J; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sambea, MA; Sánchez, P; Soriano, A | 1 |
| Gochicoa Rangel, LG; Miranda Novales, MG; Palacios Saucedo, G; Solórzano Santos, F; Vázquez Rosales, G | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P | 1 |
| Bernard, M; Bouhour, D; Boulliat, J; Fleury, J; Laurent-Coriat, C; Tilikete, C; Vighetto, A | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J | 1 |
| Gładysz, A; Knysz, B; Rzeszutko, M; Zalewska, M | 1 |
| Boyd, MA; Burger, DM; Cooper, DA; Duncombe, CJ; Hassink, EA; Khongphattanayothin, M; Lange, J; Phanuphak, P; Reiss, P; Ruxrungtham, K; Srasuebkul, P; Stek, M; Ubolyam, S | 1 |
| Burger, D; de Groot, R; van der Lee, M; Verweel, G | 1 |
| DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B | 1 |
| Bartlett, JA; Griffith, S; Herrera, G; Irlbeck, D; Johnson, J; Liao, Q; Rodriguez, A; Shaefer, MS; Sosa, N | 1 |
| Albrecht, M; Benson, C; da Silva, BA; Eron, J; Glesby, M; Gulick, R; Hanna, GJ; Hicks, C; Kessler, H; King, MS; Landay, A; McMillan, FI; Murphy, R; Thompson, M; White, AC; Wolfe, P | 1 |
| Certain, A; Clavel, F; Costagliola, D; Dalban, C; Descamps, D; Duval, X; Launay, O; Mouajjah, S; Peytavin, G; Ralaimazava, P; Verdon, R | 1 |
| Al-Sharqui, A; Manavi, K; McDonald, A | 1 |
| Becker, S; Bernstein, B; Calhoun, D; Cameron, DW; da Silva, B; Foit, C; Hanna, GJ; King, MS; Klein, C; Tokimoto, D | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| David, N; Hammond, J; Krantz, E; Malan, DR; McGrath, D; Wirtz, V | 1 |
| Díaz-Curiel, M; Fernández-Guerrero, ML; García-Delgado, R; Górgolas, M; Goyenechea, A; Rivas, P | 1 |
| Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
| Chauvin, JP; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Ghosn, J; Girard, PM; Horban, A; Norton, M; Rouzioux, C; Taburet, AM; Van, PN | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; De Luca, A; Gianotti, N; Lorenzini, P; Maggiolo, F; Mussini, C; Nasto, P; Perno, CF; Torti, C; Trotta, MP | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Bresson, JL; Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Galimand, J; Ghosn, J; Girard, PM; Peytavin, G; Raffi, F; Rouzioux, C | 1 |
| Boue, F; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Marcellin, F; Norton, M; Raffi, F; Spire, B; Van Philippe, N | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Berrisford, AE; Boulle, AM; Jaspan, HB | 1 |
| Burty, C; Christian, B; Ghomari, K; May, T; Pavel, S; Pouaha, J; Rabaud, C; Vermersch, A; Yazdanpanah, Y | 1 |
| Babiker, AG; Cotton, MF; Gibb, DM; Jean-Philippe, P; Madhi, SA; McIntyre, JA; Steyn, J; Violari, A | 1 |
| Abbasi, NR; Wang, N | 1 |
| Baxter, L; Bryant, J; Hird, S | 1 |
| Allavena, C; Cahn, P; Clotet, B; Côté, H; Harris, M; Montaner, J; Negredo, E; Ochoa, C; Raffi, F; Singer, J; Thorne, A; Zala, C | 1 |
| Moreno, V; Valencia, ME | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Bernstein, BM; Campo, RE; Chiu, YL; Cotte, L; Da Silva, BA; Gathe, JC; Gazzard, B; Hicks, CB; King, MS; Klein, CE | 1 |
| Mathew, M; McComsey, G; McGrath, D; Rightmire, A; Wirtz, V; Yang, R | 1 |
| DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Adlington, R; Richens, J; Shahmanesh, M | 1 |
| García-Lázaro, M; Natera, C; Rivero, A; Villar, C | 1 |
| Alabi, A; Corrah, T; Cotten, M; Jallow, S; Janssens, W; Jaye, A; McConkey, SJ; Peterson, K; Rowland-Jones, S; Sarge-Njie, R; Vanham, G; Whittle, H | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Lips, P; Reiss, P; Ristola, M; Sutinen, J; van Agtmael, MA; van Vonderen, MG | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Jaeger, H; Norton, M; Raffi, F; Rouzioux, C; Shürmann, D; Taburet, AM; Van, PN | 1 |
| Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Arribas López, JR | 1 |
| Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Girard, PM; Ngovan, P; Norton, M; Raffi, F | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Gorowara, M; Jupimai, T; Pancharoen, C; Phasomsap, C; Puthanakit, T; Ruxrungtham, K; van der Lugt, J | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR | 1 |
| Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C | 1 |
| Bellos, N; Dejesus, E; Murphy, D; Patel, LG; Ross, LL; Shaefer, MS; Squires, KE; Wannamaker, PG; Young, B; Zhao, HH | 1 |
| Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Allen, L; Castles, MA; Huang, DB; Huang, F; MacGregor, TR; Moy, F; Nguyen, T; Robinson, P; Rowland, L; Vinisko, R | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Boué, F; Briot, K; Cohen-Codar, I; Delfraissy, JF; Flandre, P; Knysz, B; Kolta, S; Morlat, P; Norton, M; Pintado, C; Rode, R; Roux, C; Valantin, MA; Van, PN | 1 |
| Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
| de Carvalho, AM; Espiridião, S; Fontes, TM; Kulay Júnior, L; Nakamura, MU; Simões, RS; Wagner, A | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Avettand-fenoel, V; Blanche, S; Briand, N; Chaix, ML; Frange, P; Mahlaoui, N; Moshous, D; Rouzioux, C; Veber, F | 1 |
| Gold, WL; Koblic, PM; la Porte, CJ; Lee, TC | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| de Carvalho, LP; Espiridiao, S; Fontes, TM; Kulay, L; Nakamura, MU; Oliveira-Filho, RM; Simões, RS; Wagner, A | 1 |
| Carroll, SL; Jacobson, IV; Milross, CG; Post, JJ; Varma, R | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Azzoni, L; Firnhaber, C; Foulkes, AS; Fox, L; Glencross, DK; Gross, R; Hunt, G; Montaner, LJ; Morris, L; Sanne, I; Schulze, D; Stevens, W; Van Amsterdam, D; Yin, X | 1 |
| Aïssi, E; Ettahar, N; Huleux, T; Massongo, M; Melliez, H; Pasquet, A; Yazdanpanah, Y | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Ananthakrishnan, S; Garg, A; Levine, D | 1 |
| Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Teruya, K; Tsukada, K | 1 |
| Borderi, M; Calza, L; Colangeli, V; Grossi, G; Manfredi, R; Motta, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Ascenzi, P; Ivanovic, J; Montesano, C; Narciso, P; Notari, S; Pucillo, LP; Sergi, M | 1 |
| Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Capeau, J; Danner, SA; Domingo, P; Feeney, ER; Mallon, PW; Reiss, P; van Agtmael, MA; van Vonderen, MG; Villarroya, F; Wit, F | 1 |
| Fätkenheuer, G; Hartmann, P; Jung, N; Lehmann, C; Rubbert, A; Schömig, E; Taubert, D | 1 |
| Abel, F; Behrens, G; Domingo, P; Maserati, R; Pearce, G; Rieger, A; Wang, H | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH | 1 |
| Hofmeyr, J; Kankasa, C; Karamagi, C; Meda, N; Nagot, N; Neveu, D; Nikodem, C; Sommerfelt, H; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Patel, F; Shiau, S; Strehlau, R | 2 |
| Cauda, R; Ciccarelli, N; Cingolani, A; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Farina, S; Mondi, A; Murri, R; Navarra, P; Sidella, L; Tamburrini, E | 1 |
| Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Holmes, D | 1 |
| Perelson, AS; Zhang, J | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B | 1 |
| Gisolf, EH; Langebeek, N; Legrand, J; Nieuwkerk, PT; Reiss, P; Richter, C; Sprangers, MA; Sprenger, HG | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Sax, PE | 1 |
| Andrade-Villanueva, J; Arribas, JR; Cahn, P; Figueroa, MI; Gatell, JM; Lama, JR; Norton, M; Patterson, P; Rolon, MJ; Sierra Madero, J; Sued, O | 1 |
| Lee, D; Nguyen, NH; Yee, BE | 1 |
| Asensi, V; Bachiller, P; Blanco, JR; Camacho, A; Castaño, M; Clotet, B; Curto, J; Espinosa, N; Flores, J; Force, L; Gomez-Sirvent, JL; Imaz, A; Iribarren, JA; Knobel, H; López Bernaldo De Quirós, JC; Martín, T; Moreno, V; Ocampo, A; Perez, I; Podzamczer, D; Rojas, J; Rozas, N; Valencia, E; Vergas, J; Viciana, P | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Cai, J; Xiao, J; Zhang, Q | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S | 1 |
| Che, J; Chen, X; Cheng, Y; Dong, T; Meng, Q; Qian, X; Tong, B | 1 |
| Chen, M; Girgis, S; Graham, D; Mason, AL; McDougall, C; Montano-Loza, A; Sharon, D; Sis, B; Wasilenko, ST; Zhang, G | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez, MA; Santiuste, C | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Moreira, J | 1 |
| Fukutake, K; Goseki, Y; Hara, S; Kobayashi, M; Kuriiwa, F; Mizukami, H; Takata, Y; Yoshida, K | 1 |
| Alves, M; Guidet, B; Janneau-Magrino, L; Legendre, N; Pateron, D; Yordanov, Y | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Córdoba Iturriagagoitia, A; Mitxelena Ezeiza, J; Santesteban Muruzábal, R; Yanguas Bayona, I | 1 |
| Borghetti, A; Cauda, R; Ciccarelli, N; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Mondi, A | 1 |
| Barlow-Mosha, L; Cotton, M; Dominguez, K; Ford, N; Penazzato, M | 1 |
| Donnen, P; Koy, T; Malandala, GL; Mukumbi, H; Wilmet-Dramaix, M | 1 |
| Arribas, JR; Cabié, A; Crespo, M; Domingo, P; Dronda, F; Estrada, V; Gatell, JM; Girard, PM; Iribarren, JA; Knobel, H; Landman, R; Mallolas, J; Martínez-Rebollar, M; Montero, M; Pich, J; Podzamczer, D; Portilla, J; Pulido, F; Weiss, L; Zamora, FX | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Henry, K; LaMarca, A; Ross, LL; Schneider, S; Shaefer, MS; Squires, KE; Tashima, K; Young, B; Zhao, HH | 1 |
| Bhatti, L; DeJesus, E; Edelstein, H; Margolis, DA; Ross, LL; Shaefer, MS; Small, CB; Weinberg, WG; Wohl, DA; Zhao, HH | 1 |
| Amed, AM; Araujo Júnior, E; Júnior, LK; Nakamura, MU; Simões, J; Vangelotti, AM | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Ayudhaya, OP; Bouazza, N; Cressey, TR; Foissac, F; Ingsrisawang, L; Jittayanun, K; Jourdain, G; Jungpipun, J; Lallemant, M; Le Coeur, S; Ngo-Giang-Huong, N; Puangsombat, A; Sripan, P; Srirompotong, U; Traisathit, P; Tréluyer, JM; Urien, S | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Blanche, S; Engebretsen, IMS; Hofmeyr, GJ; Jackson, D; Kankasa, C; Kwagala, M; Lombard, C; Maréchal, V; Meda, N; Mwiya, M; Nagot, N; Ndeezi, G; Neboua, D; Neveu, D; Rekacewicz, C; Rutagwera, D; Singata, M; Siuluta, C; Some, E; Sommerfelt, H; Sunday, A; Traore, H; Tumwine, JK; Tylleskär, T; Vallo, R; Van de Perre, P | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Balogun, K; Banko, N; Loutfy, M; MacGillivray, J; Mohammadi, H; Murphy, KE; Papp, E; Serghides, L; Shah, R; Silverman, M; Walmsley, SL; Yudin, MH | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Ananworanich, J; Chokephaibulkit, K; Do, VC; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Sudjaritruk, T; Teeraananchai, S; Truong, KH | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Carpio, F; DeJesus, E; Fusco, G; Fusco, J; Henegar, C; Hsu, R; Lackey, P; Mills, A; Pierone, G; Wohlfeiler, M | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Beniowski, M; Cozzi-Lepri, A; Duvivier, C; Edwards, S; Falconer, K; Hassoun, G; Kuznetsova, A; Kuzovatova, E; Laut, K; Llibre, JM; Losso, M; Maltez, F; Mitsura, V; Mocroft, A; Paredes, R; Pedersen, C; Ristola, M; Stellbrink, HJ; Szlavik, J; Vullo, V | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Blanche, S; Blume, J; Bouazza, N; Foissac, F; Harper, K; Hirt, D; Illamola, SM; Kankasa, C; Meda, N; Nagot, N; Singata-Madliki, M; Tréluyer, JM; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Barlow-Mosha, L; Borkowsky, W; Chen, J; Chi, BH; Deygoo, N; Duffy, PE; Gabriel, EE; Hobbs, CV; Ilmet, T; Jean Philippe, P; Kamthunzi, P; Kirmse, B; Li, Y; Mofenson, L; Musoke, P; Neal, J; Palumbo, P; Parikh, S; Petzold, E; Prescott, W; Tauzie, J; Tegha, G | 1 |
| Alteri, C; Bernardi, S; Bertoli, A; Liuzzi, G; Manno, EC; Palma, P; Perno, CF; Rossi, P; Tchidjou, HK; Zangari, P | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Estany, C; Estrada, V; Gutiérrez, MD; Mateo, GM; Negredo, E; Ornelas, A; Puig, J; Toro, J | 1 |
| Antinori, A; Borghetti, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Francisci, D; Grima, P; Latini, A; Madeddu, G; Mondi, A; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Belmonti, S; Castagna, A; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Callard, RE; Klein, NJ; Lewis, J; Majekodunmi, AO; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Avit, D; Blanche, S; Coulibaly, M; Dahourou, DL; Eboua, F; Kalmogho, A; Lepage, P; Leroy, V; Malateste, K; Meda, N; N'Gbeche, S; Ouédraogo, R; Ouédraogo, S; Salamon, R; Seguin-Devaux, C; Timité-Konan, M; Toni, T; Van de Perre, P; Yonaba, C | 1 |
| Bagenda, L; Bertagnolio, S; Easterbrook, PJ; Hakim, J; Hoppe, A; Kambugu, A; Kiconco, M; Kityo, C; Mugyenyi, P; Nankya, I; Paton, NI; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Domínguez-Castro, M; Figueroa-Damián, R; Flores-García, Z; Hernández-Pineda, J; Loaiza-Flores, G; López-Martínez, M; Plazola-Camacho, N; Ramírez-Ramírez, A; Rodríguez-Delgado, RG; Sánchez-Serrano, E | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Antinori, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Avino, A; d'Ettorre, G; De Luca, A; Del Pin, B; Di Giambenedetto, S; Fabbiani, M; Focà, E; Francisci, D; Gagliardini, R; Grima, P; Latini, A; Lombardi, F; Madeddu, G; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Castagna, A; Cauda, R; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Garner, O; Iardino, A; Lorusso, G; Lotta, F | 1 |
| Crespo, M; Esteban, H; Gutiérrez, F; Hernández-Quero, J; Iribarren, JA; Mariño, A; Pasquau, J; Pérez-Molina, JA; Pérez-Valero, I; Rivero, A; Rubio, R; Santos, J; Sanz, J; Terrón, A | 1 |
| Alejos, B; Arribas, JR; Coscia, C; De Luca, A; Di Giambenedetto, S; Gatell, JM; Moreno, S; Perez-Molina, JA; Pitch, J; Pulido, F; Ribera, E; Zamora, J | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| de Oliveira, MA; Franco, JB; Martins E Martins, F; Maureira Pena, LJ; Ortega, KL | 1 |
| Chasela, CS; Corbett, A; Davis, NL; Hudgens, MG; Jamieson, DJ; Kaullen, J; Kourtis, AP; Miller, WC; Nelson, JAE; Sichali, D | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Moreno, A; Rodriguez-Sagrado, MA; Vivancos, MJ | 1 |
| Blanche, S; Engebretsen, I; Kankasa, C; Meda, N; Mwiya, M; Nagot, N; Peries, M; Singata-Madliki, M; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Powis, KM; Siberry, GK | 1 |
| Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y | 1 |
| Aizire, J; Boivin, MJ; Familiar-Lopez, I; Fowler, MG; Kawalazira, R; Kuteesa, A; Maliwichi-Senganimalunje, L; Mallewa, M; Mutebe, A; Namukooli, JL; Nyakato, M; Ogwang, LW; Ruiseñor-Escudero, H; Sikorskii, A; Taha, TE | 1 |
| Elhenawee, M; Saleh, H; Saraya, RE | 1 |
| Chen, GJ; Chen, JH; Cheng, CY; Cheng, SH; Hung, CC; Hung, TC; Wei, JL | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Amaro, C; Azurara, L; Miroux-Catarino, A; Monteiro, AF; Silva, L; Viana, I | 1 |
| Barreto, J; Borrego, P; Gomes, P; Gonçalves, F; Moranguinho, I; Rocha, J; Taveira, N | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
| Domínguez-Castro, M; Figueroa-Damián, R; Galindo-Sevilla, N; Hernández-Pineda, J; Irles, C; Jung-Cook, HH; Katende-Kyenda, NL; Ramírez-Ramírez, A; Romo-Yañéz, J | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Batra, H; Chawla, H; Das, BK; Hussain, AW; Kabra, SK; Katpara, S; Kumar, S; Lodha, R; Luthra, K; Singh, R; Singh, S | 1 |
| Åstrøm, AN; Birungi, N; Engebretsen, IMS; Fadnes, LT; Tumwine, JK | 1 |
| Andrade Villanueva, J; Arribas, JR; Belaunzaran-Zamudio, PF; Cahn, P; Camiro-Zuñiga, A; Cecchini, DM; Crabtree-Ramírez, B; Figueroa, MI; Fink, VI; Gun, A; Lama, JR; Lopardo, G; Patterson, P; Sierra Madero, J; Sued, OG | 1 |
| Aweeka, F; Bradford, S; Browning, R; Coletti, A; Costello, D; Graham, B; Hughes, E; Kamthunzi, P; Kawalazira, R; Mmbaga, BT; Moye, J; Musoke, P; Nathoo, K; Norman, J; Owor, M; Purdue, L; Reding, C; Tierney, C; Whalen, ME; Wiesner, L; Ziemba, L | 1 |
| Bangirana, P; Batting, J; Cournil, A; Engebretsen, IMS; Kankasa, C; Meda, N; Molès, JP; Mwiya, M; Nagot, N; Nalugya, J; Ndeezi, G; Peries, M; Perre, PV; Quillet, C; Singata-Madliki, M; Tassembedo, S; Tonga, MW; Tumwine, J; Tylleskär, T | 1 |
| Dallocchio, RN; De Vito, A; Delogu, G; Dessì, A; Madeddu, G; Serra, PA | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Eggers, Y; Feldt, T; Fuchs, A; Häussinger, D; Heger, E; Hurissa, Z; Jarso, G; Jensen, BO; Kaiser, R; Knops, E; Lübke, N; Luedde, T; Orth, HM; Tufa, TB | 1 |
| Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI | 1 |
| Andrieux-Meyer, I; Bekker, A; Capparelli, E; Cotton, MF; Cressey, R; Cressey, TR; du Toit, S; Groenewald, M; Kumar, M; Lallemant, M; Nielsen, J; Rabie, H; Salvadori, N; Than-In-At, K | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Chen, H; Deng, Y; Gao, Y; Ge, X; Ge, Y; Lan, G; Li, B; Li, S; Liu, S; Luo, H; Luo, L; Meng, Q; Qin, G; Qin, H; Wang, Y; Wen, P; Wu, X; Yang, H; Zhu, J; Zhu, Q | 1 |
| Cai, C; Dai, X; Wang, R; Yang, W; Zhong, M | 1 |
| Ambe Chenwi, C; Angong Beloumou, G; Dambaya, B; Djupsa Ndjeyep, SC; Fokam, J; Ka'e, AC; Kouanfack, C; Mbopi Keou, FX; Mbouyap, PR; Mossiang, L; Ndjolo, A; Ngoufack Jagni Semengue, E; Nka, AD; Takou, D; Teto, G | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
20 review(s) available for lamivudine and ritonavir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Ritonavir.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; CD4-Positive T-Lymphocytes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocyte Count; Randomized Controlled Trials as Topic; Ritonavir; RNA, Messenger; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir | 1997 |
Antiviral chemotherapy.
Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease Inhibitors; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
[Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Bundle-Branch Block; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Heart; Heart Block; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Syncope; Zidovudine | 2002 |
Non-occupational postexposure prophylaxis for HIV: a systematic review.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Databases, Bibliographic; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Lopinavir; Premedication; Pyrimidinones; Ritonavir; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Unsafe Sex; Zidovudine | 2009 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Nevirapine; Post-Exposure Prophylaxis; Pregnancy; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir; Zidovudine | 2015 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.
Topics: Data Interpretation, Statistical; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Randomized Controlled Trials as Topic; Ritonavir; Viral Load | 2018 |
Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mouth Neoplasms; Ritonavir; Sarcoma, Kaposi; Zidovudine | 2019 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
143 trial(s) available for lamivudine and ritonavir
| Article | Year |
|---|---|
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dendritic Cells; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Image Processing, Computer-Assisted; In Situ Hybridization; Kinetics; Lamivudine; Leukocytes, Mononuclear; Macrophages; Palatine Tonsil; Proviruses; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Male; Palatine Tonsil; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
Topics: Anti-HIV Agents; Cell Line, Transformed; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocytes, Cytotoxic; Viral Load; Zidovudine | 1998 |
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Topics: Adult; Anti-HIV Agents; Antigens; B-Lymphocytes; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Antigens; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypersensitivity, Delayed; Lamivudine; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocyte Subsets; Time Factors; Zidovudine | 1998 |
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Observation; Risk Factors; Ritonavir; Saquinavir; Treatment Failure; Viral Load; Zidovudine | 1998 |
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; RNA, Viral; T-Lymphocytes, Cytotoxic; Time Factors; Viremia; Virus Replication; Zidovudine | 1999 |
[Experiences with antiretroviral combination therapy].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; N-Glycosyl Hydrolases; Retrospective Studies; Ritonavir; RNA, Viral; Zidovudine | 1999 |
Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Genotype; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Mutation; Pilot Projects; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Severity of Illness Index; Time Factors; Viral Load; Zidovudine | 1999 |
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.
Topics: Anti-HIV Agents; Apoptosis; Cell Cycle; Cross-Sectional Studies; DNA; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 1999 |
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Follow-Up Studies; HIV-1; Humans; Immunologic Memory; Lamivudine; Lymphocyte Count; Lymphocytes; Reference Values; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocytes; Time Factors; Viral Load; Zidovudine | 1999 |
Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
Topics: Anti-HIV Agents; Confidence Intervals; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 1999 |
Saquinavir therapy in patients with the advanced HIV infection and liver cirrhosis.
Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Liver Cirrhosis; Ritonavir; Saquinavir; Stavudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Topics: Anti-HIV Agents; Complement Pathway, Classical; Complement System Proteins; Drug Administration Schedule; Drug Therapy, Combination; HIV Antibodies; HIV Antigens; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 1999 |
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
Topics: Anti-HIV Agents; Candida; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; Humans; Hypersensitivity, Delayed; Immune System; Lamivudine; Mumps virus; Ritonavir; RNA, Viral; Zidovudine | 2000 |
Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2000 |
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 2000 |
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Time Factors; Viral Load; Zidovudine | 2000 |
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Therapy, Combination; Female; Hemocyanins; Hepatitis A Vaccines; HIV-1; Humans; Hypersensitivity, Delayed; Injections, Intradermal; Lamivudine; Male; Middle Aged; Ritonavir; T-Lymphocytes; Tetanus Toxoid; Thymus Gland; Vaccination; Viral Hepatitis Vaccines; Zidovudine | 2000 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Female; Germany; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; White People | 2000 |
Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cell Differentiation; Child; Coculture Techniques; Female; HIV Infections; HIV-1; Humans; Immunophenotyping; Infant; Lamivudine; Leukocytes, Mononuclear; Male; Nelfinavir; Prospective Studies; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Virus Replication; Zidovudine | 2000 |
Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antigens, Viral; Base Sequence; CD4-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Mice; Mice, SCID; Molecular Sequence Data; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sequence Analysis, DNA; Viral Load; Zidovudine | 2000 |
Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2000 |
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
Treatment for primary infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Controlled Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Placebos; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Mutation; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2001 |
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Time; Viral Load; Zidovudine | 2001 |
HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymph Nodes; Lymphocyte Subsets; Lymphocytes; Male; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Viral Load; Viremia; Virus Replication | 2001 |
Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Morbidity; Prognosis; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 2001 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Administration Schedule; Humans; Lamivudine; Nelfinavir; Nevirapine; Patient Compliance; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2002 |
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load | 2002 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.
Topics: Adult; Anti-HIV Agents; Blood-Brain Barrier; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunoglobulin G; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine | 2003 |
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Genes, MDR; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ritonavir; RNA, Viral; Zidovudine | 2003 |
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load | 2004 |
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine; Time Factors | 2004 |
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Lamivudine; Male; Metabolic Clearance Rate; Ritonavir; Stavudine; Zidovudine | 2004 |
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load | 2004 |
Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2005 |
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Topics: Administration, Oral; Adult; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Hospitals; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Thailand | 2005 |
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.
Topics: Age Factors; Antiretroviral Therapy, Highly Active; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Male; Maximum Tolerated Dose; Prospective Studies; Risk Assessment; Ritonavir; Severity of Illness Index; Single-Blind Method; Survival Rate; Treatment Outcome; Zidovudine | 2005 |
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Saquinavir; Spain; Treatment Outcome; Tuberculosis | 2005 |
Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Indinavir; Lamivudine; Male; Ritonavir; RNA, Viral; Stavudine; Thailand; Treatment Outcome; Viral Load; Withholding Treatment | 2005 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Disease Progression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine; Zidovudine | 2006 |
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Ritonavir; RNA, Viral; Time Factors; Viral Load; Zidovudine | 2006 |
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Zidovudine | 2006 |
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Oxazines; Ritonavir; Stavudine; Treatment Outcome | 2006 |
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Endpoint Determination; Female; France; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Species Specificity; Viral Load | 2006 |
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Zidovudine | 2007 |
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Topics: Adult; Aged; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Stavudine; Viral Load; Withholding Treatment | 2008 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Semen; Time Factors; Virus Shedding; Zidovudine | 2008 |
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
Early antiretroviral therapy and mortality among HIV-infected infants.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Failure; Zidovudine | 2008 |
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2009 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Medication Adherence; Plasma; Pyrimidinones; Ritonavir; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Pyridines; Ritonavir; Stavudine | 2009 |
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2009 |
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Osteoporosis; Pyrimidinones; Ritonavir; Young Adult; Zidovudine | 2009 |
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Topics: Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Zidovudine | 2009 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Topics: Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Male; Medication Adherence; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Zidovudine | 2010 |
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2010 |
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Clinical Protocols; Cohort Studies; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Nevirapine; Pregnancy; Pyrimidinones; Research Design; Ritonavir; Zidovudine | 2011 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Azepines; Drug Combinations; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult; Zidovudine | 2012 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Fat Distribution; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; HIV Infections; Lamivudine; Lopinavir; Protease Inhibitors; Ritonavir; Stavudine; Zidovudine | 2011 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Zidovudine | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Atrophy; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Subcutaneous Fat; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV; HIV Infections; Humans; Lamivudine; Lipids; Lopinavir; Male; Medication Adherence; Middle Aged; Organophosphorus Compounds; Ritonavir; Treatment Outcome | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult | 2013 |
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pregnancy; Ritonavir; Treatment Outcome | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; South Africa; Stavudine | 2013 |
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult | 2013 |
A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Netherlands; Odds Ratio; Patient Satisfaction; Quality of Life; Ritonavir; Zidovudine | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Double-Blind Method; Drug Combinations; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Peptide Fragments; Peptides; Ritonavir | 2014 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Bone Density; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Kidney; Lamivudine; Lipids; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Thailand; Viral Load; Zidovudine | 2016 |
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pre-Exposure Prophylaxis; Ritonavir | 2016 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lactams, Macrocyclic; Lamivudine; Macrocyclic Compounds; Male; Middle Aged; Oxazines; Piperazines; Proline; Pyridones; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Malaria, Falciparum; Malawi; Male; Nevirapine; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2016 |
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Viral Load | 2017 |
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Viral Load; Young Adult | 2017 |
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2017 |
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Burkina Faso; Child, Preschool; Cote d'Ivoire; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Public Health; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2018 |
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inflammation; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2018 |
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Child; Child, Preschool; Dental Caries; Drug Therapy, Combination; Female; Gingivitis; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Oral Health; Outcome Assessment, Health Care; Prevalence; Quality of Life; Ritonavir; Tooth Eruption; Uganda | 2020 |
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Topics: Africa South of the Sahara; Anti-HIV Agents; Area Under Curve; Child, Preschool; Chromatography, Liquid; Cohort Studies; Drug Combinations; Drug Elimination Routes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Patient Safety; Ritonavir; Severe Acute Malnutrition; Tandem Mass Spectrometry; Zidovudine | 2021 |
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Topics: Anti-HIV Agents; Burkina Faso; Chemoprevention; Child; Child Development; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Neuropsychological Tests; Ritonavir; South Africa; Surveys and Questionnaires; Uganda; Zambia | 2021 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Topics: Adenosine Monophosphate; Adult; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Healthy Volunteers; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Tenofovir; Uganda | 2021 |
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Lamivudine; Lopinavir; Ritonavir | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
193 other study(ies) available for lamivudine and ritonavir
| Article | Year |
|---|---|
The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
Topics: Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Etoposide; Flow Cytometry; HIV Protease Inhibitors; Humans; Multidrug Resistance-Associated Proteins; Probenecid; Reverse Transcriptase Inhibitors; Ritonavir; Tumor Cells, Cultured | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
New drugs for HIV infection.
Topics: Antiviral Agents; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Zalcitabine | 1996 |
[HIV: to administer protease inhibitors early].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Time Factors; Zalcitabine; Zidovudine | 1996 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Protease inhibitor therapy in children with perinatally acquired HIV infection.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Protease Inhibitors; Retrospective Studies; Ritonavir; Saquinavir; Stavudine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Nonprogressive CMV retinitis in AIDS patients with protease inhibitors therapy for AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug Therapy, Combination; Fundus Oculi; Ganciclovir; HIV Protease Inhibitors; Humans; Lamivudine; Male; Ritonavir; Saquinavir | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.
Topics: Animals; Anti-HIV Agents; Chronic Disease; Drug Resistance, Microbial; Drug Therapy, Combination; Fetal Tissue Transplantation; Flow Cytometry; HIV Infections; HIV-1; Lamivudine; Leukocytes, Mononuclear; Liver Transplantation; Mice; Mice, SCID; Recurrence; Ritonavir; RNA, Viral; Saquinavir; Thymus Gland; Viremia; Zidovudine | 1998 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Brain; CD4 Lymphocyte Count; Child; Cognition Disorders; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Magnetic Resonance Imaging; Male; Psychological Tests; Ritonavir; Virus Replication; Zidovudine | 1998 |
Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; T-Lymphocytes, Cytotoxic; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
Taste and smell complaints in HIV-infected patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Clarithromycin; Didanosine; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Quality of Life; Ritonavir; Smell; Surveys and Questionnaires; Taste; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1998 |
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation; Biomarkers; Female; HIV Infections; HLA-DR Antigens; Humans; Lamivudine; Leukocyte Common Antigens; Lymphocyte Activation; Lymphocyte Count; Male; Membrane Glycoproteins; NAD+ Nucleosidase; Prospective Studies; Ritonavir; RNA, Viral; T-Lymphocytes; Viral Load; Zidovudine | 1998 |
Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Female; Graves Disease; Humans; Immunity; Indinavir; Lamivudine; Male; Ritonavir; Stavudine | 1998 |
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Female; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 1998 |
Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Erythrocyte Transfusion; HIV Infections; Humans; Immunoglobulins, Intravenous; Lamivudine; Male; Parvoviridae Infections; Parvovirus B19, Human; Red-Cell Aplasia, Pure; Remission Induction; Ritonavir; Saquinavir; Zidovudine | 1999 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cytokines; Female; Gene Expression; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-13; Interleukin-2; Interleukin-4; Lamivudine; Longitudinal Studies; Male; Receptors, CCR3; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; Receptors, Interleukin; Receptors, Interleukin-12; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; Saquinavir; Zidovudine | 1999 |
Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Zidovudine | 1999 |
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Zidovudine | 1999 |
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cerebrospinal Fluid; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunophenotyping; Lamivudine; Lymphocyte Activation; Lymphoid Tissue; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load | 1999 |
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.
Topics: Codon; Drug Resistance, Microbial; Evolution, Molecular; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Lamivudine; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir | 1999 |
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Quality of Life; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sickness Impact Profile; Zidovudine | 1999 |
Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Denmark; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Multicenter Studies as Topic; Retrospective Studies; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.
Topics: Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocytes; Male; Middle Aged; Ritonavir; T-Lymphocyte Subsets; Thymus Gland; Tomography; Zidovudine | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Factor VII Deficiency; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2000 |
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Time Factors | 2000 |
HE2000 shows efficacy.
Topics: Animals; Anti-HIV Agents; Disease Models, Animal; Drugs, Investigational; Haplorhini; Lamivudine; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Survival Analysis; Viral Load; Zidovudine | 1999 |
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Disease Reservoirs; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Stavudine; Viral Load; Zidovudine | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Mitochondria; Perinatal Care; Peroxisomes; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2000 |
Assessing efficacy by measuring CD(4) counts and quality of life of AIDS patients treated with ritonavir, AZT and 3TC.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Humans; Lamivudine; Male; Quality of Life; Ritonavir; Viral Load; Zidovudine | 2000 |
Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease.
Topics: Adult; Aged; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Female; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Scintillation Counting; Statistics, Nonparametric; Stavudine; T-Lymphocyte Subsets; Tritium; Viral Load | 2000 |
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Viral Load; Zidovudine | 2001 |
AIDS treatments seek to eradicate virus, restore immunity.
Topics: Adjuvants, Immunologic; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; Humans; Lamivudine; Ritonavir; Thymus Gland; Viral Load; Zidovudine | 1996 |
ACTG 315 drug cocktail restores immune function.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 1997 |
Ritonavir pediatric study results reported.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lamivudine; Ritonavir; Zidovudine | 1998 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors shine in triple combinations.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
New findings bring hope to Vancouver AIDS conference.
Topics: Adult; AIDS Vaccines; Antiviral Agents; Clinical Trials as Topic; Developing Countries; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
ICAAC update.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1996 |
To AIDS and back with Norvir, D4T, 3TC and nutritional therapies. An interview with Michael Golk.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Dietary Fats; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Killer Cells, Natural; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Triglycerides | 1998 |
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Didanosine; Drug Evaluation; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Safety; Treatment Outcome; Triglycerides; Viral Load | 2001 |
Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.
Topics: Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HLA-DR Antigens; Humans; Lamivudine; Leukocyte Common Antigens; Longitudinal Studies; Lymphocyte Count; Male; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; T-Lymphocyte Subsets; Viral Load; Zidovudine | 2001 |
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hypergammaglobulinemia; Immunoglobulin G; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2001 |
[HIV-HBV coinfection and the liver].
Topics: Biopsy; Didanosine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Ritonavir; Saquinavir; Stavudine | 2001 |
Clinical trials group: two studies are now open to patients who qualify.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Zidovudine | 2000 |
Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Apoptosis; Case-Control Studies; Caspase 3; Caspase 8; Caspase 9; Caspases; CD3 Complex; CD4 Lymphocyte Count; fas Receptor; Female; HIV Infections; Humans; In Vitro Techniques; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes | 2002 |
Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; France; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 2002 |
Gynaecomastia associated with combination antiretroviral therapy including protease inhibitors for human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Diagnosis, Differential; Drug Therapy, Combination; Gynecomastia; HIV Infections; HIV Protease Inhibitors; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Saquinavir; Stavudine | 1999 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Liver Function Tests; Male; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sex Factors; Transaminases | 2002 |
New drugs.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Approval; Drug Combinations; Humans; Lamivudine; Lopinavir; Pyrimidinones; Ritonavir; Zidovudine | 2001 |
Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery.
Topics: Acidosis, Lactic; Anti-HIV Agents; Aortic Valve; Female; Heart Valve Prosthesis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Failure, Chronic; Lamivudine; Middle Aged; Postoperative Complications; Renal Dialysis; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2002 |
[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Viremia; Zidovudine | 2003 |
Latrogenic nephrogenic diabetes insipidus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Diabetes Insipidus, Nephrogenic; HIV Infections; Humans; Indinavir; Lamivudine; Male; Ritonavir; Stavudine | 2003 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Disease Progression; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Gastrointestinal Neoplasms; Herpesviridae Infections; Herpesvirus 4, Human; Herpesvirus 8, Human; HIV-1; Humans; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prednisone; Ritonavir; Saquinavir; Sarcoma, Kaposi; Skin Neoplasms; Stavudine; Tumor Virus Infections; Vincristine | 2003 |
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Stavudine; Zidovudine | 2003 |
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine | 2003 |
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Oligopeptides; Organophosphonates; Oxazines; Pregnancy; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Treatment Outcome; Viral Load; Zidovudine | 2004 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Fluconazole; Flucytosine; HIV Infections; Humans; Immunologic Memory; Lamivudine; Lopinavir; Male; Meningitis, Cryptococcal; Pyrimidinones; Recurrence; Ritonavir; Syndrome; T-Lymphocyte Subsets; Zidovudine | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hypertriglyceridemia; Infant; Lamivudine; Male; Ritonavir; Saquinavir; Zidovudine | 2006 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
[HIV infection presenting with bilateral optic neuropathy].
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Facial Nerve Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ischemia; Lamivudine; Lopinavir; Male; Meningitis, Viral; Methylprednisolone; Middle Aged; Optic Disk; Optic Nerve Diseases; Polyradiculopathy; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Visual Fields; Zidovudine | 2006 |
Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carcinoma, Small Cell; Fatal Outcome; HIV Seropositivity; Humans; Lamivudine; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Ritonavir; Saquinavir; Zidovudine | 2006 |
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine | 2007 |
Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Case-Control Studies; Dideoxynucleosides; Femur Neck; HIV Infections; Humans; Lamivudine; Lopinavir; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Zidovudine | 2008 |
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Thymidine; Treatment Outcome | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Lopinavir; Male; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2008 |
Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lamivudine; Male; Organophosphates; Prospective Studies; Ritonavir; Sulfonamides; Zidovudine | 2008 |
Doxorubicin-induced hyperpigmentation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carbamates; Doxorubicin; Drug Combinations; Furans; Humans; Lamivudine; Lip Diseases; Male; Melanosis; Nails, Malformed; Organophosphates; Ritonavir; Sarcoma, Kaposi; Sulfonamides; Tongue Diseases; Zidovudine | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
First-line antiretroviral therapy in resource-limited settings: time to reconsider?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
[Raised tattoos in a human-immunodeficiency-virus-infected patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Hepatitis C, Chronic; Histiocytes; Humans; Lamivudine; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Lopinavir; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Patient Compliance; Pentamidine; Pyrimidinones; Recurrence; Ritonavir; Tattooing; Zidovudine | 2009 |
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Gambia; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Pyrimidinones; Ritonavir; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.
Topics: Anti-HIV Agents; Antifungal Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Monitoring; HIV Infections; Humans; Interferon-gamma; Lamivudine; Male; Meningitis, Cryptococcal; Pyrimidines; Ritonavir; Serum; Triazoles; Voriconazole; Young Adult | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
[Morphological and physiological analysis of livers and kidneys of pregnant rats and their fetuses treated by the association of zidovudine, lamivudine and ritonavir for the whole period of pregnancy].
Topics: Animals; Anti-HIV Agents; Female; Fetus; Kidney; Lamivudine; Liver; Pregnancy; Rats; Rats, Wistar; Ritonavir; Zidovudine | 2010 |
Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Mutation; Paris; Pyrimidinones; Ritonavir; Treatment Failure | 2011 |
Medication-based urolithiasis and atazanavir.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Uric Acid; Urinary Calculi; Urolithiasis | 2011 |
Chronic action of association of zidovudine, lamivudine and ritonavir on pregnant rats. A biologic assay.
Topics: Animals; Animals, Newborn; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Female; Lamivudine; Litter Size; Pregnancy; Pregnancy, Animal; Random Allocation; Rats; Rats, Wistar; Ritonavir; Statistics, Nonparametric; Zidovudine | 2011 |
Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Humans; Lamivudine; Lopinavir; Lymphoma, AIDS-Related; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nasopharyngeal Neoplasms; Pyrimidinones; Radiotherapy, Adjuvant; Remission Induction; Ritonavir; Viral Load; Zidovudine | 2011 |
[Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Axilla; Clarithromycin; Darunavir; Dideoxynucleosides; Enfuvirtide; Ethambutol; HIV Envelope Protein gp41; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Isoniazid; Lamivudine; Lymph Node Excision; Lymphadenitis; Male; Mycobacterium avium-intracellulare Infection; Peptide Fragments; Pyrazinamide; Rifampin; Ritonavir; Streptomycin; Sulfonamides | 2011 |
Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.
Topics: Adenine; Adrenal Insufficiency; Adult; Atazanavir Sulfate; Cushing Syndrome; Cytochrome P-450 Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Iatrogenic Disease; Injections, Intramuscular; Lamivudine; Oligopeptides; Organophosphonates; Pruritus; Pyridines; Ritonavir; Tenofovir; Triamcinolone Acetonide | 2011 |
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Topics: Adult; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Pilot Projects; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Limit of Detection; Lopinavir; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Zidovudine | 2012 |
Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Cytidine Triphosphate; Dideoxynucleotides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Phosphorylation; Real-Time Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Tandem Mass Spectrometry; Transfection; Young Adult | 2013 |
Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus.
Topics: Age Factors; Anthropometry; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Ritonavir; South Africa; Stavudine; Time Factors; Treatment Outcome | 2013 |
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
Topics: Adiposity; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Bone and Bones; Cognition; Drug Resistance, Viral; Endpoint Determination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Oligopeptides; Patient Compliance; Pilot Projects; Pregnancy; Pyridines; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2013 |
Talk of HIV cure goes viral.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Nevirapine; Primary Prevention; Ritonavir; Secondary Prevention; Time Factors; Zidovudine | 2013 |
Contribution of follicular dendritic cells to persistent HIV viremia.
Topics: Dendritic Cells, Follicular; Drug Combinations; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lopinavir; Models, Biological; Ritonavir; Stavudine; Viral Load; Viremia; Virus Release | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Initial therapy for HIV: can less be more?
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Combinations; Drug Hypersensitivity Syndrome; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Lopinavir; Pleural Effusion; Postpartum Period; Pyrrolidinones; Radiography; Raltegravir Potassium; Respiratory Distress Syndrome; Ritonavir; Zidovudine | 2014 |
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Spain; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Post-Exposure Prophylaxis; Retrospective Studies; Ritonavir; Zidovudine | 2014 |
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Topics: Administration, Oral; Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Dideoxynucleosides; Drug Combinations; Drug Dosage Calculations; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Models, Statistical; Ritonavir; Silybin; Silymarin; Viral Load; Zidovudine | 2015 |
Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease.
Topics: Amino Acid Sequence; Animals; Anti-Retroviral Agents; Biomarkers; Cholangitis; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Lamivudine; Liver Cirrhosis, Biliary; Lopinavir; Mammary Tumor Virus, Mouse; Mice, Inbred NOD; Molecular Sequence Data; Protease Inhibitors; Retroviridae Infections; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Time Factors; Tumor Virus Infections; Viral Load; Zidovudine | 2015 |
Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Synergism; HIV Infections; Humans; Lamivudine; Ritonavir; Sulfonamides; Treatment Outcome | 2015 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Barriers to simplified HIV treatment in low-resource settings.
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy.
Topics: Anti-Bacterial Agents; Clarithromycin; Death, Sudden, Cardiac; Dideoxynucleosides; Drug Combinations; Drug Interactions; Electrocardiography; Fatal Outcome; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Piperazines; Purines; Ritonavir; Sexual Behavior; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
Topics: Adult; Antiviral Agents; Bipolar Disorder; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Synergism; Drug Therapy, Combination; Ergotism; Female; HIV Infections; Humans; Hypotension, Orthostatic; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Vasoconstrictor Agents; Zidovudine | 2015 |
[Cutaneous CD8+ T-cell lymphoma. Regression after HIV antiviral triple therapy].
Topics: Alopecia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Clone Cells; Dideoxynucleosides; Drug Therapy, Combination; Humans; Immunophenotyping; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Ritonavir | 2015 |
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2015 |
[Comparative and evolutionary profile of people infected with HIV on antiretroviral therapy in Kinshasa, Democratic Republic of Congo].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Democratic Republic of the Congo; Disease Progression; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Zidovudine | 2014 |
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir | 2015 |
Chronic action of lamivudine and ritonavir on maternal and fetal liver and kidney of albino pregnant rats (Rattus norvegicus albinus, Rodentia, Mammalia): morphological and biochemical aspects.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Retroviral Agents; Drug Evaluation, Preclinical; Female; Kidney; Lamivudine; Liver; Pregnancy; Pregnancy Complications, Infectious; Rats; Rats, Wistar; Ritonavir | 2015 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.
Topics: 20-alpha-Hydroxysteroid Dehydrogenase; Animals; Anti-HIV Agents; Cells, Cultured; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Mice; Mice, Inbred C57BL; Placenta; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prolactin; Ritonavir; Trophoblasts; Zidovudine | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Indonesia; Lamivudine; Male; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; Vietnam; Viral Load; Zidovudine | 2016 |
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocytes, Mononuclear; Pilot Projects; Polymerase Chain Reaction; Ritonavir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2017 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
Topics: Adult; Age Factors; Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Sex Factors; Viral Load | 2016 |
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
Topics: Anti-HIV Agents; Bayes Theorem; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Ritonavir | 2017 |
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Nevirapine; Phylogeny; Ritonavir; Zidovudine | 2016 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Coinfection; Drug Combinations; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lamivudine; Lopinavir; Male; Models, Immunological; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Ribavirin; Ritonavir; Time-to-Treatment; Zidovudine | 2017 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Calibration; Chromatography, High Pressure Liquid; Colostrum; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Young Adult; Zidovudine | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
Headache in an HIV-Positive Patient: Dangerous Interaction.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Cilostazol; Cytochrome P-450 CYP3A Inhibitors; Dideoxynucleosides; Drug Combinations; Drug Interactions; Enoxaparin; Ergotamine; Ergotism; Headache; HIV Infections; Humans; Ischemia; Lamivudine; Lower Extremity; Male; Nitroglycerin; Ritonavir; Saquinavir; Tetrazoles; Tibial Arteries; Ultrasonography, Doppler, Color; Vasoconstrictor Agents; Vasodilator Agents | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Antiretroviral Drug Concentrations in Breastmilk, Maternal HIV Viral Load, and HIV Transmission to the Infant: Results From the BAN Study.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Pregnancy; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zidovudine | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; CD4-CD8 Ratio; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Function Tests; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Optimising HIV antiretrovirals for mothers and infants.
Topics: Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Mothers; Ritonavir | 2019 |
Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Malawi; Male; Post-Exposure Prophylaxis; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Uganda; Zidovudine | 2019 |
Silver Nanoparticles Synthesis for Sensitive Spectrophotometric Determination of Sofosbuvir, Lamivudine, and Ritonavir in Pure Forms and Pharmaceutical Dosage Forms.
Topics: Excipients; Lamivudine; Metal Nanoparticles; Ritonavir; Silver; Sofosbuvir | 2020 |
Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sustained Virologic Response; Viral Load | 2019 |
Pediatric Kaposi's sarcoma associated with immune reconstitution inflammatory syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Dideoxynucleosides; Drug Therapy, Combination; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Ritonavir; Sarcoma, Kaposi | 2020 |
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Topics: Anti-HIV Agents; Cabo Verde; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2020 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Seropositivity; Humans; Lamivudine; Lopinavir; Patient Safety; Pregnancy; Ritonavir; Tandem Mass Spectrometry; Viral Load; Zidovudine | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Ritonavir; Viral Load; Zidovudine | 2020 |
The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2021 |
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Emtricitabine; Humans; Lamivudine; Lopinavir; Molecular Docking Simulation; Nucleosides; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2021 |
Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Ethiopia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Viral Load | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Short-term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo.
Topics: Animals; Anti-HIV Agents; Female; HIV Infections; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Mammals; Mice; Rats; Ritonavir; Zidovudine | 2023 |
Dose-response and type-dependent effects of antiviral drugs in anaerobic digestion of waste-activated sludge for biogas production.
Topics: Anaerobiosis; Antiviral Agents; Biofuels; Bioreactors; COVID-19; Humans; Lamivudine; Methane; Pandemics; Ritonavir; Sewage; Waste Disposal, Fluid | 2023 |
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2023 |
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |